The PlexPCR® SARS-CoV-2 assay can help your laboratory regain efficiency through pandemic and post-pandemic testing. Based on our PlexZyme® technology, targeting highly conserved regions (RdRp/ORF1ab), and with automation compatibility – your laboratory can easily stay on top of COVID-19 testing and the supply challenges the pandemic has brought.
SARS-CoV-2 continues to mutate, giving rise to variants potentially impacting diagnostic testing and reporting. Reliable and accurate diagnostics are required by laboratories to save time, resources, and to have confidence in the data reported.
SpeeDx routinely monitors the ability of our PlexPCR® SARS-CoV-2 assay to detect emerging COVID variants. We have determined that our sequences match those seen in the recently reported Omicron variant, as well all other previously identified variants, to provide assurance that your laboratory can confidently report test results. Learn more.
Effective COVID-19 management is dependent on reliable and frequent testing. Disruptions in global manufacturing supply chains continue to limit availability of laboratory diagnostic kits, impacting local testing strategies.
SpeeDx utilises PlexZyme® technology, de-coupling the detection probe from the primer sequence to produce universal probes which can be used across our entire product portfolio. Our production can stockpile probes well in excess of ‘market demand’ to negate supply chain constraints. This enables us to readily ship kits in high volumes at all times – ensuring no interruptions to your daily laboratory testing. Learn more.
SpeeDx ResistancePlus® diagnostics detect the infecting organism and antibiotic susceptibility or resistance markers – empowering clinicians to make informed patient treatment decisions.
Resistance Guided Therapy (RGT) uses advances in diagnostic technology to help clinicians choose the best targeted therapy for individual patients based on the resistance status of their infection.
Strategies for controlling many STIs are dependent on the availability of inexpensive yet highly effective antibiotics. As antimicrobial resistance rates rise in these infections it is even more important to use our limited antibiotics more wisely.
Guidelines for management of STIs caused by Mycoplasma genitalium and Neisseria gonorrhoeae increasingly recommend RGT to help:
Declining cure rates when employing detection-only practices for M. genitalium addressed with implementation of RGT, increasing cure rates for macrolide susceptible populations to 95% and total population cure rate over 92%.1
Improve cure rate and simplify patient management.
ResistancePlus® tests give your laboratory a competitive advantage. Now you can offer your clinicians more than just detection. The combination of resistance data with infection detection in a single-well test, enables RGT for improved patient management.
PlexPCR® tests combine multiple, clinically relevant infectious disease targets into a single test solution. ResistancePlus® tests combine organism detection with genetic markers linked to antibiotic susceptibility or resistance.
ResistancePlus® tests combine organism detection with genetic markers linked to antibiotic susceptibility or resistance. PlexPCR® tests combine multiple, clinically relevant infectious disease targets into a single test solution.
Provision of SARS-CoV-2 tests reinforces PNG sovereign capacity to respond to ongoing pandemic. SpeeDx announce they have donated ...18 October, 2022
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have added a new product to their portfolio; PlexMonke...10 October, 2022
Our mission is to deliver innovative clinical diagnostics to improve patient outcomes. Meet the SpeeDx Team, learn about our key collaborations and partnerships, and join our passion to change the face of diagnostics.
1Read TRH et al. Clinical Infectious Diseases 2019; 68(4):554-560
2Harris SR et al. Lancet Infect Dis Published online May 15th 2018
3Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015
4Heffernan H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-5
5Kirkcaldy RD et al. MMWR Surveillance Summaries July 15, 2016 / 65(7);1–19